Dr. Paul Richardson is the Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute and an RJ Corman Professor of Medicine at Harvard Medical School. He has led several novel, biologically-derived translational efforts in multiple myeloma and has been the co recipient of the ASH Ernest Beutler Prize for clinical science and translational research in 2015, the COMY Award for multiple myeloma research (Paris, France) in 2016, and the IMF Robert A. Kyle Lifetime Achievement Award in 2017.
Dr. Richardson has led the study and clinical development of numerous novel drugs in the treatment of multiple myeloma which have contributed to improvement in outcome for patients over the last 15 years. In addition, he has published in many leading peer-reviewed publications including The New England Journal of Medicine, Blood, Journal of Clinical Oncology, Lancet Oncology, Lancet Haematology, Clinical Cancer Research, Bone Marrow Transplantation, JAMA Oncology, and the British Journal of Haematology. He is a member of the Developmental Therapeutics and Lymphoma and Myeloma Df/HCC Programs.
